The absence of formal cash flow reporting, combined with a 3.68 P/FCF multiple, suggests that distributions may be increasingly reliant on Return of Capital rather than sustainable cash inflows from portfolio exits.
| Metric | Dec'24 | Dec'23 | Dec'22 | Dec'21 |
|---|
| Cash from Operations | 277.21M | 216.57M | 310.48M | -4.64B |
| Operating CF Margin % | 681.26% | 100.46% | -18.78% | 725.17% |
| Operating CF Growth % | 28% | -30.25% | 106.69% | - |
| Net Income | 35.7M | 211.57M | -1.66B | -640.65M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 247.57M | -15.36M | 1.97B | -4.01B |
| Working Capital Changes | -6.06M | 20.37M | -6.34M | 9.34M |
| Change in Receivables | 266.19K | -99.73K | 228.99K | -462.13K |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 |
| Cash from Investing | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | -277.21M | -216.57M | -310.51M | 4.64B |
| Debt Issued (Net) | 0 | 0 | -139.78K | 139.78K |
| Equity Issued (Net) | -1000K | -1000K | -1000K | 1000K |
| Dividends Paid | -184.73M | -176.11M | -235.85M | -161.27M |
| Share Repurchases | -92.49M | -40.46M | -74.53M | -61.87M |
| Other Financing | 354 | 0 | 0 | 0 |
| Net Change in Cash | -367 | 32 | -30.77K | -68.9K |
| Free Cash Flow | 277.21M | 216.57M | 310.48M | -4.64B |
| FCF Margin % | 681.26% | 100.46% | -18.78% | 725.17% |
| FCF Growth % | 28% | -30.25% | 106.69% | - |
| FCF per Share | 1.28 | 1.00 | 1.30 | -18.68 |
| FCF Conversion (FCF/Net Income) | 7.76x | 1.02x | -0.19x | 7.24x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
NAV discount and liquidity
As the trust does not provide a formal statement of cash flows, the absence of data prevents a direct reconciliation between net income and operating cash flow, leaving investors unable to verify if reported earnings are supported by actual cash inflows from portfolio exits or dividend distributions.
The reliance on marked-to-model valuations for private assets suggests that reported net income may significantly diverge from cash reality. Without transparent cash flow reporting, the quality of earnings remains speculative, as investors cannot distinguish between realized gains and unrealized valuation adjustments.
Based on the trust's operational mandate, the trajectory of free cash flow is inherently volatile, as it is tied to the timing of liquidity events in private biotechnology holdings rather than consistent, recurring operational cash generation from a traditional business model.
The -81.13% revenue decline suggests that the trust's ability to generate cash through asset sales has stalled, which may force management to rely on existing cash reserves or debt to maintain distributions. This trajectory warrants caution, as the lack of cash flow visibility complicates the assessment of long-term dividend sustainability.
According to institutional analysis of the trust's distribution policy, there is a heightened risk that capital deployment is being funded through Return of Capital rather than genuine investment income, which may erode the trust's net asset value over the long term.
Investors should monitor whether distributions are being financed by the liquidation of core holdings during a market downturn. If cash deployment continues to outpace realized investment gains, the trust may face a structural decline in its ability to participate in future private equity rounds.
As indicated by the trust's reliance on Level 3 asset valuations, the financial statements likely obscure the true cash-generating potential of the portfolio, as these models often fail to account for the liquidity premiums required to exit private biotechnology positions in a stressed market.
The absence of cash flow data prevents an assessment of whether the trust is effectively managing its liquidity needs or if it is becoming overly reliant on external financing. This lack of transparency suggests that the market's current discount to NAV may be a rational response to the uncertainty surrounding the actual cash value of the underlying assets.
Quick answers to the most common questions about buying BTX stock.
BlackRock Technology and Private Equity Term Trust (BTX) generated $277.2M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
BlackRock Technology and Private Equity Term Trust (BTX) generated $277.2M in free cash flow in 2024. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
BlackRock Technology and Private Equity Term Trust (BTX) spent $0.0M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2024, BlackRock Technology and Private Equity Term Trust (BTX) returned $184.7M to shareholders via cash dividends and spent $92.5M on share repurchases. This shows the company's commitment to returning capital to its equity investors.